[{"id":"96f0f596-bee1-42fc-9dcc-41fcf8f78f40","acronym":"SL03-OHD-105","url":"https://clinicaltrials.gov/study/NCT05483933","created_at":"2022-08-02T12:55:49.417Z","updated_at":"2025-02-25T15:27:30.695Z","phase":"Phase 1","brief_title":"Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers","source_id_and_acronym":"NCT05483933 - SL03-OHD-105","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-11"},{"id":"809acd3d-0f20-4fcc-9b3f-5f01fafa10a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05456685","created_at":"2022-07-13T12:56:36.433Z","updated_at":"2025-02-25T17:31:27.306Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05456685","lead_sponsor":"AbbVie","biomarkers":" FOLR1 • BRCA","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 09/28/2022","start_date":" 09/28/2022","primary_txt":" Primary completion: 05/12/2026","primary_completion_date":" 05/12/2026","study_txt":" Completion: 05/12/2026","study_completion_date":" 05/12/2026","last_update_posted":"2025-01-30"},{"id":"36b25a6e-d1bc-4c39-aec7-9e1f51d0310f","acronym":"ZOLAR","url":"https://clinicaltrials.gov/study/NCT06537596","created_at":"2025-02-26T09:09:12.436Z","updated_at":"2025-02-26T09:09:12.436Z","phase":"Phase 1","brief_title":"89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT06537596 - ZOLAR","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","biomarkers":" PDGFRA","pipe":" | ","alterations":" FOLR1 expression","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lartruvo (olaratumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-12-19"},{"id":"023cf6d7-38d4-4089-89bb-ebee230e66e8","acronym":"GLORIOSA","url":"https://clinicaltrials.gov/study/NCT05445778","created_at":"2022-07-06T15:54:42.215Z","updated_at":"2024-07-02T16:34:26.631Z","phase":"Phase 3","brief_title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)","source_id_and_acronym":"NCT05445778 - GLORIOSA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA • MUC16","pipe":" | ","alterations":" FOLR1 expression • MUC16 elevation","tags":["FOLR1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 418","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-06-13"},{"id":"80a15019-c76b-402b-869e-abfd7ab973d5","acronym":"PRO1184-001","url":"https://clinicaltrials.gov/study/NCT05579366","created_at":"2022-10-13T16:56:38.872Z","updated_at":"2024-07-02T16:35:06.017Z","phase":"Phase 1/2","brief_title":"PRO1184 for Advanced Solid Tumors","source_id_and_acronym":"NCT05579366 - PRO1184-001","lead_sponsor":"ProfoundBio US Co.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-03"},{"id":"85edd770-3ac8-453d-88dc-75e0a0a175d3","acronym":"PICCOLO","url":"https://clinicaltrials.gov/study/NCT05041257","created_at":"2021-09-13T15:55:27.708Z","updated_at":"2024-07-02T16:35:08.475Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)","source_id_and_acronym":"NCT05041257 - PICCOLO","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA","pipe":" | ","alterations":" FOLR1 expression • BRCA mutation","tags":["FOLR1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 01/17/2024","primary_completion_date":" 01/17/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-04-22"},{"id":"95fe996a-08c8-4bbd-9a80-6d6d99bc679d","acronym":"REFRaME-O1","url":"https://clinicaltrials.gov/study/NCT05870748","created_at":"2023-05-23T16:06:11.980Z","updated_at":"2024-07-02T16:35:08.676Z","phase":"Phase 2/3","brief_title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","source_id_and_acronym":"NCT05870748 - REFRaME-O1","lead_sponsor":"Sutro Biopharma, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression • FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-19"},{"id":"bd7ac170-f9ec-4021-bd06-e5f2697c1c6d","acronym":"ELU-FRα-1","url":"https://clinicaltrials.gov/study/NCT05001282","created_at":"2021-08-11T14:55:40.694Z","updated_at":"2024-07-02T16:35:12.374Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","source_id_and_acronym":"NCT05001282 - ELU-FRα-1","lead_sponsor":"Elucida Oncology","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELU001"],"overall_status":"Recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-28"},{"id":"d152c3ba-cce4-4f26-ae10-9617725a91a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05378737","created_at":"2023-12-22T17:17:42.298Z","updated_at":"2024-07-02T16:35:25.446Z","phase":"Phase 1","brief_title":"Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection","source_id_and_acronym":"NCT05378737","lead_sponsor":"Bio-Thera Solutions","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-22"},{"id":"ea2b2cd9-de2b-48c3-a36f-f7e33e0ebe95","acronym":"","url":"https://clinicaltrials.gov/study/NCT04606914","created_at":"2021-01-19T20:31:38.308Z","updated_at":"2024-07-02T16:35:27.611Z","phase":"Phase 2","brief_title":"Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04606914","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" BRCA","pipe":" | ","alterations":" FOLR1 expression","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2023-11-30"},{"id":"7ea7b76e-29f6-4753-a54f-be730ae868af","acronym":"MIRASOL","url":"https://clinicaltrials.gov/study/NCT04209855","created_at":"2021-01-18T20:30:11.495Z","updated_at":"2024-07-02T16:35:54.021Z","phase":"Phase 3","brief_title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","source_id_and_acronym":"NCT04209855 - MIRASOL","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-03-06"},{"id":"7dbbc938-f2df-43be-869e-296694ec3653","acronym":"","url":"https://clinicaltrials.gov/study/NCT02593227","created_at":"2021-01-18T12:35:08.510Z","updated_at":"2024-07-02T16:36:27.756Z","phase":"Phase 2","brief_title":"Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT02593227","lead_sponsor":"Marker Therapeutics, Inc.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TPIV200 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2021-07-19"},{"id":"fe040a95-8a63-460a-9602-c2d63a78dd68","acronym":"MORAB-003-J081-102","url":"https://clinicaltrials.gov/study/NCT01049061","created_at":"2021-01-18T04:07:17.178Z","updated_at":"2024-07-02T16:36:44.265Z","phase":"Phase 1","brief_title":"A Study of MORAb-003 in Patients With Solid Tumor","source_id_and_acronym":"NCT01049061 - MORAB-003-J081-102","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e farletuzumab (MORAB-003)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 02/01/2013","study_completion_date":" 02/01/2013","last_update_posted":"2020-06-11"}]